Patents by Inventor Simon Mbua Ngale Efange

Simon Mbua Ngale Efange has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIHYDRO-SPIRO[INDOLINE-3:1'-iSOQUINOLIN]-2-ONES AS ANTIMALARIAL AGENTS
    Publication number: 20230132973
    Abstract: The present invention is directed to the antimalarial activity of various 3?,4?-dihydro-2?H-spiro[indoline-3:1?-isoquinolin]-2-ones and related compounds. The present invention is also directed to the use of these compounds as antimalarial agents, in the treatment of malaria. In addition, the invention relates to pharmaceutical compositions comprising one or more of these compounds alone or in combination with other therapeutic agents for the treatment and/or radical cure of severe acute malaria. The invention is also directed to the use of these agents alone and in combination with other agents in malaria prophylaxis, for example, by inhibiting and/or reducing the likelihood of a malaria infection.
    Type: Application
    Filed: March 16, 2021
    Publication date: May 4, 2023
    Inventors: Noella Molisa Efange, Lawrence Ayong, Maloba Mabanyi Mesembe Lobe, Simon Mbua Ngale Efange
  • Dihydro-Spiro[Indoline-3:1'-Isoquinolin]-2-Ones and Their Analogues and Derivatives and Methods of Treating Cancer and Other Diseases
    Publication number: 20220267329
    Abstract: The present invention is directed to various 3?,4?-dihydro-2?H-spiro[indoline-3:1?-isoquinolin]-2-one compounds and methods for treating disease states and/or conditions which are mediated through sphingosine-1-phosphate receptor(s). The present invention is also directed to the use of these compounds as anticancer agents and as modulators of sphingosine-1-phosphate receptor function in the treatment of disease states and/or conditions which are mediated through these receptors. In addition, the invention relates to pharmaceutical compositions comprising one or more of these compounds alone or in combination with other therapeutic agents. The invention is also directed to methods of treatment of cancer and/or conditions that may respond to the modulation of sphingosine-1-phosphate receptor function and which employ compounds of the present invention or pharmaceutical compositions comprising one or more of the compounds of this invention.
    Type: Application
    Filed: March 5, 2020
    Publication date: August 25, 2022
    Inventors: Simon Mbua Ngale Efange, Lobe Maloba Mesembe Mabanyi
  • Methods and compositions for preparing noribogaine from voacangine
    Patent number: 8742096
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: June 3, 2014
    Assignee: DemeRx, Inc.
    Inventors: Robert M. Moriarty, Simon Mbua Ngale Efange
  • METHODS AND COMPOSITIONS FOR PREPARING NORIBOGAINE FROM VOACANGINE
    Publication number: 20120253037
    Abstract: Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine.
    Type: Application
    Filed: March 14, 2012
    Publication date: October 4, 2012
    Inventors: Robert M. Moriarty, Simon Mbua Ngale Efange
  • Azavesamicols
    Patent number: 5876694
    Abstract: A method for non-invasively mapping cholinergic innervation in a living brain comprises injecting the brain with a radiolabelled vesamicol (hydroxylated phencyclidine (PCP) isomer trans-2-(4-phenyl-piperidino)cyclohexanol) derivatives with anticholinergic properties termed herein "azavesamicols" in which the cyclohexyl group of vesamicol is replaced with heterocycle of similar size, the piperidyl ring. The radiolabel is then detected externally with a photoscanning device.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: March 2, 1999
    Assignees: Regents of the University of Minnesota, Regents of the University of California
    Inventors: Simon Mbua Ngale Efange, Stanley M. Parsons
  • Azavesamicols
    Patent number: 5789420
    Abstract: The compounds are vesamicol (hydroxylated phencyclidine (PCP) isomer trans-2-(4-phenyl-piperidino)cyclohexanol) derivatives with anticholinergic properties termed herein "azavesamicols" in which the cyclohexyl group of vesamicol is replaced with a heterocycle of similar size, the piperidyl ring. The compounds bind to the vesamicol receptor, a cytoplasmically-oriented site on the cholinergic synaptic vesicle, which is associated with the vesicular transporter of acetylcholine.
    Type: Grant
    Filed: September 17, 1993
    Date of Patent: August 4, 1998
    Assignee: Regents of the University of Minnesota
    Inventors: Simon Mbua Ngale Efange, Stanley M. Parsons
  • Radiopharmaceutical agents for the detection of Alzheimers disease
    Patent number: 5721243
    Abstract: Novel anticholinergics which are related to vesamicol are particularly useful when radiolabeled for evaluating cholinergic innervation in the living human brain. The cholinergic deficit in the Alzheimer's brain should be identifiable with these radioligands.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: February 24, 1998
    Assignee: Regents of the University of Minnesota
    Inventors: Simon Mbua Ngale Efange, Stanley M. Parsons